33334622 31889754 30014902 34068699 35569886 28008583 28095990 34497589 29792708 34289945 34416976 29890569 27879962 28918389 30374952 27751514 27842716 30961499 29266268 32119738 28292408 29411270 30848827 27833378 32707055 34147478 32151660 2912981 - Search Results

Year	Number of Results
2016	9
2017	21
2018	18
2019	12
2020	12
2021	13
2022	1

1

Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.

Makri E, Goulas A, Polyzos SA. Makri E, et al. Arch Med Res. 2021 Jan;52(1):25-37. doi: 10.1016/j.arcmed.2020.11.010. Epub 2020 Dec 14. Arch Med Res. 2021. PMID: 33334622 Review.

2

Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.

Kothari S, Dhami-Shah H, Shah SR. Kothari S, et al. J Clin Exp Hepatol. 2019 Nov-Dec;9(6):723-730. doi: 10.1016/j.jceh.2019.06.003. Epub 2019 Jun 27. J Clin Exp Hepatol. 2019. PMID: 31889754 Free PMC article. Review.

3

Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway.

Zhao XJ, Yu HW, Yang YZ, Wu WY, Chen TY, Jia KK, Kang LL, Jiao RQ, Kong LD. Zhao XJ, et al. Redox Biol. 2018 Sep;18:124-137. doi: 10.1016/j.redox.2018.07.002. Epub 2018 Jul 5. Redox Biol. 2018. PMID: 30014902 Free PMC article.

4

Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

Perdomo CM, Garcia-Fernandez N, Escalada J. Perdomo CM, et al. J Clin Med. 2021 May 10;10(9):2040. doi: 10.3390/jcm10092040. J Clin Med. 2021. PMID: 34068699 Free PMC article. Review.

5

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Cusi K, et al. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010. Endocr Pract. 2022. PMID: 35569886 Review.

6

EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography.

Gollisch KS, Lindhorst A, Raddatz D. Gollisch KS, et al. Exp Clin Endocrinol Diabetes. 2017 Feb;125(2):116-121. doi: 10.1055/s-0042-118961. Epub 2016 Dec 22. Exp Clin Endocrinol Diabetes. 2017. PMID: 28008583

7

Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook.

Farr OM, Mantzoros CS. Farr OM, et al. Metabolism. 2017 May;70:192-195. doi: 10.1016/j.metabol.2016.12.017. Epub 2017 Jan 4. Metabolism. 2017. PMID: 28095990 Free PMC article. No abstract available.

8

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. Zhao X, et al. Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34497589 Free PMC article. Review.

9

Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Jamwal R, de la Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Jamwal R, et al. Mol Pharm. 2018 Jul 2;15(7):2621-2632. doi: 10.1021/acs.molpharmaceut.8b00159. Epub 2018 Jun 11. Mol Pharm. 2018. PMID: 29792708 Free PMC article.

10

Preparing for the NASH epidemic: A call to action.

Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Kanwal F, et al. Metabolism. 2021 Sep;122:154822. doi: 10.1016/j.metabol.2021.154822. Epub 2021 Jul 19. Metabolism. 2021. PMID: 34289945 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results